Mahamaya Lifesciences (BOM:544611) Notes Receivable: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544611 Mahamaya Lifesciences Ltd BOM:544611
16 GF Score
Price ₹166.45
! 4 Warning Signs
View Full Analysis

What is Mahamaya Lifesciences Notes Receivable?

Mahamaya Lifesciences BOM:544611 16 Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:544611 with a GF Score™ of 16/100. The stock has 4 warning signs investors should review.

Mahamaya Lifesciences's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0 Mil.

Mahamaya Lifesciences Notes Receivable Related Terms

Mahamaya Lifesciences Notes Receivable Historical Data

* Premium members only.

The historical data trend for Mahamaya Lifesciences's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mahamaya Lifesciences Notes Receivable Chart

Mahamaya Lifesciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
0.00 0.00 0.00 0.00 0.00

Mahamaya Lifesciences Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Mar26
Notes Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
BOM:544611
16GF Score
Mahamaya Lifesciences Ltd BOM:544611
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mahamaya Lifesciences Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0 Mil mean?
Mahamaya Lifesciences (BOM:544611) has a Notes Receivable of ₹0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Mahamaya Lifesciences and its competitors.
Is Mahamaya Lifesciences' Notes Receivable too high?
Mahamaya Lifesciences' current Notes Receivable is ₹0 Mil. Overall, Mahamaya Lifesciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Mahamaya Lifesciences' Notes Receivable compare to CTVA and CF?
Mahamaya Lifesciences' Notes Receivable of ₹0 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for an Agriculture company?
A good Notes Receivable depends on the Agriculture industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Mahamaya Lifesciences and its competitors. Mahamaya Lifesciences's current Notes Receivable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mahamaya Lifesciences stock overvalued right now?
Mahamaya Lifesciences (BOM:544611) has a current Notes Receivable of ₹0 Mil. The current Notes Receivable is ₹0 Mil. Mahamaya Lifesciences' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Mahamaya Lifesciences (BOM:544611), the current Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mahamaya Lifesciences Business Description

Address Sohna Road, Sector-49, Unit No. 369, 370, 370A & 370B, 3rd Floor, Prime Tower-B1, Spaze ITech Park, Gurugram, HR, IND, 122018
Mahamaya Lifesciences Ltd specializes in the manufacturing of pesticide formulations and supplies bulk formulations catering to both Indian agrochemical companies as well as multinational corporations (MNCs). The company's offerings include Insecticides, Herbicides, and Fungicides. Geographically, it serves multiple Indian states including Punjab, Haryana, Rajasthan, and Uttar Pradesh, and internationally serves countries like the Dominican Republic, Turkey, Egypt, and the UAE. The company generates revenue from the sale of its pesticide formulations.
16GF Score

Get the complete analysis for BOM:544611

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹166.45
Price